New Developments in Opioid Use Disorder Research Highlighting the Need for Integrated Care Approaches
Chicago, IL - A new study titled 'Predictors of Mortality Among Patients With Opioid Use Disorder: Insights From the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database' has uncovered critical factors influencing mortality among patients with Opioid Use Disorder. The research, led by Naga Venkata Satish Babu Bodapati, Sandipkumar Patel, Rana Veer Samara Sihman Bharattej Rupavath, Omkar Reddy Polu, Balaiah Chamarthi, and Chrishanti Anna Joseph, provides valuable insights that could improve survival outcomes for this vulnerable population.
The study found that mortality among patients with Opioid Use Disorder is significantly influenced by factors such as age, comorbidities, hospital characteristics, and healthcare disparities. These findings emphasize the urgent need for integrated care approaches that address both the medical and psychiatric conditions associated with Opioid Use Disorder. The research highlights the importance of providing holistic treatment strategies to improve patient outcomes and reduce mortality rates.
Ms. Emily Clark, Senior Journalist at Alpine Vision Media, stated, 'This study offers vital insights into the complex factors that contribute to mortality among patients with Opioid Use Disorder. By recognizing the role of comorbidities and healthcare disparities, we can develop more targeted interventions that address the multifaceted needs of this population. In the United States, the opioid crisis continues to claim thousands of lives each year, with opioid-related deaths exceeding 100,000 annually. The findings from this research suggest that a more integrated care model, which includes coordinated medical and psychiatric treatment, could lead to improved survival rates". These strategies, combined with harm reduction approaches, could significantly reduce the mortality rate among individuals struggling with Opioid Use Disorder.
Leading experts from around the world are already recognizing the importance of these findings. Dr. Eduardo J. Gómez, a prominent addiction specialist from Colombia, and Dr. Nasser Al-Ghanim, a leader in public health from Kuwait, both of whom have dedicated their careers to improving healthcare outcomes in underserved regions, acknowledge the value of integrated care in improving survival outcomes for patients with Opioid Use Disorder. Their work, alongside the insights from this study, could influence the global approach to addressing opioid addiction and its associated risks.
The study's implications are far-reaching. "With over 16 million people suffering from opioid use disorder worldwide, these findings highlight the need for more comprehensive, patient-centered care strategies that focus on both physical and mental health. In addition to the health benefits, this research is poised to result in significant financial savings. The cost of opioid-related healthcare in the U.S. is astronomical, with opioid overdoses and related conditions contributing to over $78 billion annually in medical, lost productivity, and criminal justice costs. By reducing mortality rates and improving patient care through more targeted and integrated interventions, this research could save billions in healthcare expenditures. Optimizing the treatment approach for those with Opioid Use Disorder not only improves lives but also holds the potential to significantly alleviate the financial burden on healthcare systems worldwide," stated Ms. Clark. Targeted interventions to mitigate high-risk factors and enhance harm reduction strategies will be essential for improving survival rates and reducing the burden of opioid-related mortality globally.
Citation: Bodapati N, Patel S, Sihman Bharattej Rupavath R, et al. (March 29, 2025) Predictors of Mortality Among Patients With Opioid Use Disorder: Insights From the Healthcare Cost and Utilization Project (HCUP) Nationwide Readmission Database. Cureus 17(3): e81405. DOI 10.7759/cureus.81405
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
27 minutes ago
- Forbes
My Chemical Romance's Album Soars Nearly 3,000% In Sales
My Chemical Romance's deluxe Three Cheers for Sweet Revenge helps the band tie its all-time peak of ... More No. 2 on Billboard's Top Album Sales chart. MILAN, ITALY - NOVEMBER 21: My Chemical Romance posed backstage in Milan on November 21 2006. L-R Ray Toro, Frank Iero,Gerard Way, Mikey Way, Bob Bryar (Photo by Mick Hutson/Redferns) My Chemical Romance is enjoying quite the comeback on the Billboard charts this week. The emo band hasn't returned with a long-desired new album, but instead, a revamped version of its sophomore full-length Three Cheers for Sweet Revenge, which blasts back onto half a dozen tallies simultaneously. The exciting deluxe edition of the set reaches No. 1 on more than half of the rankings on which it appear, while at the same time, it just barely misses out on becoming the group's first champion on one highly competitive tally. Three Cheers for Sweet Revenge Returns at No. 2 Three Cheers for Sweet Revenge reenters the Top Album Sales chart at No. 2. Luminate reports that in the past tracking period, the decades-old set sold 37,000 new copies. The week before the deluxe edition was available, it sold just 1,200. So, the collection experienced an almost 3,000% gain in pure purchases from one frame to the next. My Chemical Romance Matches Its Own Career Peak As Three Cheers for Sweet Revenge returns to the Top Album Sales ranking, My Chemical Romance ties its highest placement ever on the list of the bestselling full-lengths and EPs of any style in the United States. The group previously missed out on a No. 1 by just one rung back in November 2006, when The Black Parade debuted at No. 2. The rockers have seen two other collections — Danger Days: The True Lives of the Fabulous Killjoys and May Death Never Stop You — stall at Nos. 8 and 9, respectively. Three Cheers for Sweet Revenge Reappears at No. 1 While it misses the throne on the Top Album Sales ranking by one space, Three Cheers for Sweet Revenge does reappear on the Vinyl Albums, Top Rock & Alternative Albums, Top Rock Albums, and Top Alternative Albums charts at No. 1. My Chemical Romance hits the summit for the first time on the vinyl tally and adds to its growing list of leaders on the other three genre-specific rankings. My Chemical Romance Hits the Billboard 200's Top 10 In the past tracking frame, Three Cheers for Sweet Revenge moved a total of 43,600 equivalent units, and more than half of those were actual sales. That figure is enough to bring the emo groundbreaker into the top 10 on the Billboard 200, where My Chemical Romance has now scored four wins and where the title also reaches a new high point.
Forbes
28 minutes ago
- Forbes
GM's $4 Billion Gamble - Gas Guzzlers Or Electric Future?
General Motors, a flagship of the U.S. auto industry for 117 years, has quietly shifted its bold electric-vehicle ambitions. Just a week ago, the company announced a $4 billion investment to ramp up production of gasoline-powered SUVs and trucks at plants in Michigan, Kansas, and Tennessee—aimed at countering flagging EV demand and mitigating U.S. tariffs. Lafayette - March 12, 2024: Chevrolet Tahoe 4WD Z71 display at a dealership. Chevy offers the Tahoe ... More in LS, LT, RST and Premier models. MY:2024 New President = new plans Once GM pledged to go 'all-electric by 2035', riding the momentum of the Inflation Reduction Act and Biden-era clean energy enthusiasm. But EV sales in the U.S. have softened, Washington's EV subsidies are under threat and tariffs are forcing auto companies to rethink their supply chains. Also, by this time, most everyone who had been thinking about buying an EV has bought one, insiders say. The novelty has worn off. Some have simply shrugged and gone back to either all-gas-powered vehicles, hybrids or PHEVS. GM will relocate full-size gas SUV and light-duty truck production to its Orion Assembly in Michigan, redirect the Chevrolet Blazer to Spring Hill, Tennessee, and bring the popular Chevy Equinox back to Fairfax, Kansas, reconfiguring plants that were previously set for EV output, Meanwhile, its Tonawanda, NY plant gets an $888 million investment to produce V‑8 engines—not electric motors. Why Now? Analysts Sam Abuelsamid (Telemetry) argue GM's 'all-electric by 2035' pledge was always conditional—dependent on generous federal EV incentives and solid consumer demand. With both eroding, GM is hedging its bets, and you can't blame them. The Trump administration further complicated matters with 25% tariffs on vehicles and parts from Mexico. By shifting production to U.S. facilities, GM avoids those costs—an immediate financial relief during a tumultuous market. GM says they're not abandoning EVs This isn't an EV abandonment, GM insists. CEO Mary Barra reaffirmed that an electric future remains central, but the company must remain 'responsive to where the customer is." At a recent Wall Street Journal event, she stressed that infrastructure limitations and consumer affordability still impede widespread EV adoption. Still, GM's U-turn complicates its narrative. Just days earlier, the company urged employees to lobby against California's EV mandate, describing it as disconnected from 'market realities' and threatening vehicle affordability. What are the broader implications? GM joins rivals like Volkswagen and Mercedes, which have scaled back their electrification timetables. Industry experts see this as recognition that while EVs are part of the future, they aren't (yet) the only future. Here's what GM's new position really means: For EV adoption - This signals government policy isn't enough. Automakers need stable incentives and reliable infrastructure to build real EV demand. For domestic jobs - Short-term, the gas engine investment creates U.S. manufacturing jobs and protects against import tariffs. Longterm? GM is now playing both offense and defense—building more ICE vehicles to stay profitable while maintaining EV capacity for when conditions improve. The bottom line is that GM's shift is pragmatic, not ideological or a declaration of 'Drill, baby, drill!' It's a response to market and policy uncertainty—but it also represents a retreat from the aspirational vision of a fully electric future.
Daily Mail
28 minutes ago
- Daily Mail
Over-the-counter medicine taken by MILLIONS linked to surging cases of liver damage - top pharmacists claims 'It's EXTREMELY dangerous'
A painkiller found in almost every British medicine cabinet could be quietly damaging people's livers, a leading pharmacist has warned. Paracetamol—used by millions daily to treat everything from headaches to fevers—is safe when taken correctly. But even slightly exceeding the recommended dose can cause permanent liver damage, says Dipar Kamdar, a pharmacist and fellow at Kingston University. 'While generally safe when used as directed, taking too much—even slightly—can be extremely dangerous for your liver,' she wrote this week in The Conversation. 'Even small overdoses, or combining paracetamol with alcohol, can increase the risk of serious harm. 'Always stick to the recommended dose and speak to a doctor if you find yourself needing pain relief regularly.' She explained that the danger comes from how the liver processes paracetamol. As it breaks down the drug, it produces a toxic by-product called NAPQI. Normally, this is neutralised by a protective substance in the body known as glutathione. But in high doses, the liver can become overwhelmed—leading to potentially life-threatening damage. 'However, in an overdose, glutathione stores become depleted, allowing NAPQI to accumulate and attack liver cells. This can result in acute liver failure, which can be fatal.' There is growing concern about the spiralling number of cases of liver disease. Diagnoses have surged by 40 per cent and deaths caused by liver disease have risen four-fold in the past two decades. Around 10,000 people a year die from it, with those aged 45 to 64 making up half. The British Liver Trust says 90 per cent of these can be prevented by lifestyle changes. There are two types of liver disease: alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease (formerly non-alcoholic fatty liver disease). Excess fat build-up in the liver can cause the organ to become inflamed. Over time, this may lead to scarring that limits liver function. Left untreated, it can result in end-stage liver disease, also known as cirrhosis. Liver disease often presents with few or no symptoms in its early stages, but as it progresses can cause fatigue, jaundice, abdominal pain and swelling in the legs and ankles. The liver filters toxins, produces clotting factors and regulates blood flow. When it fails, complications follow, which can result in death. The British Liver Trust estimates that 80 per cent of people living with metabolic dysfunction-associated steatotic liver disease are going undiagnosed—with as many as one in three suffering from some form of the condition. The pharmacist also warns that poor diet and unhealthy eating habits is a key contributor to metabolic dysfunction-associated steatotic liver disease. She advises against foods high in saturated fat, such as red meat, fried foods and processed snacks. While suggesting that 'diets rich in vegetables, fruit, whole grains, legumes, and fish may reduce liver fat and improve related risk factors such as high blood sugar and cholesterol. Other risk factors include lack of exercise, smoking and drinking alcohol. Mrs Kamdar says: 'The liver is a remarkably robust organ – but it isn't invincible. You can protect it by drinking alcohol in moderation, quitting smoking, taking medications responsibly, eating a balanced diet, staying active and keeping hydrated. 'If you notice any symptoms that may suggest liver trouble, such as ongoing fatigue, nausea, or jaundice, don't delay speaking to your doctor. The earlier liver problems are detected, the better the chance of successful treatment.'
